Ligand Pharmaceuticals sees 22% CAGR in royalty revenue through 2029
Source: SeekingAlpha
2025-05-08 14:20:31 ET
More on Ligand Pharmaceuticals, Ligand Pharmaceuticals Incorporated ROCHE CONT RT, etc.
Read the full article on Seeking Alpha
For further details see:
Ligand Pharmaceuticals sees 22% CAGR in royalty revenue through 2029
Ligand Pharms Inc Cvr
NASDAQ: LGNDZ
LGNDZ Trading
0.0% G/L:
$0.002 Last:
7,245 Volume:
$0.002 Open:
LGNDZ Latest News
LGNDZ Stock Data
$3,679,103,920
18,304,000
N/A
151
N/A
Biotechnology & Life Sciences
Healthcare
US
Jupiter
